


# In allergy to house dust mites

ImmunoCAP Allergen Component testing can help you to differentiate between specific and cross-reactive allergen sensitization<sup>4</sup>


## Suggested test profile



**Thermo**  
SCIENTIFIC



## ImmunoCAP provides quantitative results for accurate decisions



**Positive test results:**  $\geq 0.10 \text{ kU}_A/\text{l}$  indicates sensitization  
In infants, even very low levels indicate risk for symptomatic allergy<sup>19,20</sup>

## ImmunoCAP can be performed without limitations

- Irrespective of patient age, skin condition, medication, disease activity and pregnancy<sup>21-24</sup>
- No precaution for severe reactions as with skin-prick test<sup>21,25</sup>

**References:** 1. Duran-Tauleria E, et al. *Allergy*. 2004;59(Suppl 78):35-41. 2. Niggemann B, et al. *Pediatr Allergy Immunol*. 2008;19:325-31. 3. Eigenmann PA, et al. *Pediatr Allergy Immunol*. 2013;24:195-209. 4. Canonica GW, et al. *World Allergy Organization Journal*. 2013;6(1):17. 5. Konradsen JR, et al. *Pediatr Allergy Immunol*. 2014;25:187-92. 6. Bjerg A, et al. *Pediatr Allergy Immunol*. 2015;26(6):557-63. 7. Thomas WR. *Human Vaccines & Immunotherapeutics*. 2012;8(10):1469-76. 8. Bessot JP and Pauli G. *Eur Ann Allergy Clin Immunol*. 2011;43:141-56. 9. O'Driscoll BR, et al. *Clin Exp Allergy*. 2009;39(11):1677-83. 10. Pongracic JA, et al. *J Allergy Clin Immunol*. 2010;125(3):593-9. 11. Gent JF, et al. *Environ Res*. 2012;118:86-93. 12. Stern DA, et al. *Lancet*. 2008;372:1058-64. 13. Kurup VP, et al. *Clin Exp Allergy*. 2000;30(7):988-93. 14. Nikolaizik WH, et al. *Am J Respir Crit Care Med*. 2002;165(7):916-21. 15. Hemmann S, et al. *Eur J Immunol*. 1998;28(4):1155-60. 16. Purkayastha S, et al. *Appl Biochem Biotechnol*. 2000;83(1-3):271-83. 17. Söderström L, et al. *Allergy*. 2003;58:921-8. 18. Sampson HA. *J Allergy Clin Immunol*. 2001;107:891-6. 19. Host A, et al. *Allergy*. 2003;58:559-69. 20. Söderström L, et al. *Allergy*. 2011;66:1058-64. 21. Siles RL, et al. *Cleve Clin J Med*. 2011;78:585-92. 22. Bonnellykke K, et al. *J Allergy Clin Immunol*. 2008;121:646-51. 23. Belhocine W, et al. *Pediatr Allergy Immunol*. 2011;22:600-7. 24. Bacharier LB, et al. *Allergy*. 2008;63:5-34. 25. Walsh J, et al. *Br J Gen Pract*. 2011;61:473-5.


[thermoscientific.com/phadia](http://thermoscientific.com/phadia)

© 2015 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific Inc. and its subsidiaries. Manufacturer: Phadia AB, Uppsala Sweden.

52-5109-62

## Discover the connection Between **allergic rhinitis** and underlying proteins

ImmunoCAP®, a two-step approach to support an accurate allergy diagnosis



**Thermo**  
SCIENTIFIC

**Thermo**  
SCIENTIFIC

A Thermo Fisher Scientific Brand

## In allergy to furry animals

ImmunoCAP Allergen Components can help you resolve multiple positivity to pet extract<sup>4</sup>

### Suggested test profile

ImmunoCAP Complete Allergens	Cat (e1)	Dog (e5)	Horse (e3)
ImmunoCAP Allergen Components	Fel d 1 (Secretoglobin) Fel d 2 (Serum albumin) Fel d 4 (Lipocalin)	Can f 1 (Lipocalin) Can f 2 (Lipocalin) Can f 3 (Serum albumin) Can f 5 (Secretoglobin)	Equ c 1 (Lipocalin)
Clinical implications	<ul style="list-style-type: none"> <li>Fel d 1 positive patients may be suitable for AIT</li> <li>Fel d 4 is associated with severe asthma/symptoms<sup>5,6</sup></li> <li>Fel d 2 indicates cross reactivity and is seldom of clinical importance, however Fel d 2 can be a primary sensitizer in Pork-Cat-Syndrome<sup>5</sup></li> </ul>	<ul style="list-style-type: none"> <li>Can f 1 / f 2 / f 5 positive patients may be suitable for AIT</li> <li>Can f 1/Can f 2/Can f 5 is associated with severe asthma/symptoms<sup>5,6</sup></li> <li>Can f 3 indicates cross reactivity and is seldom of clinical importance<sup>5</sup></li> </ul>	<ul style="list-style-type: none"> <li>Equ c 1 is a specific horse allergen component<sup>5</sup></li> <li>Equ c 1 positive patients may be suitable for AIT</li> </ul>



## In allergy to mould

ImmunoCAP Allergen Component testing can help you identify suitable allergens for AIT<sup>4</sup>

### Suggested test profile

ImmunoCAP Complete Allergens	Aspergillus fumigatus (m3) Alternaria alternata (m6) Penicillium glabrum (m209) Cladosporium herbarum (m2)
ImmunoCAP Allergen Components	rAlt a 1 Alternaria alternata  rAsp f 1 Aspergillus fumigatus rAsp f 2 Aspergillus fumigatus rAsp f 3 Aspergillus fumigatus rAsp f 4 Aspergillus fumigatus rAsp f 6 Aspergillus fumigatus
Clinical implications	<ul style="list-style-type: none"> <li>Indicates asthma risk<sup>9-12</sup></li> <li>Patient may be suitable for AIT</li> </ul> <ul style="list-style-type: none"> <li>Sensitization only to Asp f 1 and 3 is associated with asthma<sup>13</sup></li> <li>Asp f 4 and 6 seem to be specific markers for ABPA (allergic bronchopulmonary aspergillosis).<sup>14,15</sup></li> <li>High IgE levels of Asp f 1,2,4 and 6 are associated with ABPA.<sup>13,16</sup></li> </ul>



## In seasonal allergy

ImmunoCAP Allergen Component testing can help to differentiate between specific and cross-reactive allergen sensitization<sup>4</sup>

### Suggested test profile

ImmunoCAP Complete Allergen testing with relevant tree, grass and weed pollens to confirm allergy suspicion		
Species	Specific	Cross-reactive
<b>TREE</b>		
Birch	rBet v 1 (t215)	rBet v 2* (t216) rBet v 4* (t220) MUXF3** (o214)
Cypress	nCup a 1** (t226)	
Olive	rOle e 1 (t224)	
Plane tree	rPla a 1 (t241)	
<b>GRASS</b>		
Bermuda	nCan d 1** (g216)	rPhi p 7* (g210) rPhi p 12* (g212) MUXF3** (o214)
Timothy	rPhi p 1 (g205) rPhi p 5 b (g215)	
<b>WEED</b>		
Ragweed	nAmb a 1 (w230)	
Mugwort	nArt v 1 (w231) nArt v 3 (w233)	
Wall pellitory	rPar j 2 (w211)	
Plantain	rPla I 1 (w234)	
Saltwort	nSal k 1** (w232)	
<b>Indication for AIT</b>		Uncertain AIT efficacy, especially in absence of pollen specific sensitization. <b>Continue to search for the specific component.</b>

\* Birch or timothy profilins (Bet v 2, Phi p 12) and polyclains (Bet v 4, Phi p 7) can replace the corresponding components in other pollens due to the high degree of similarity.

\*\* Glycoprotein containing CCD (cross-reactive carbohydrate determinants). IgE antibodies to CCD alone are not clinically relevant.